11 June 2021

Johnson & Johnson Statement on Supply of COVID-19 Vaccine in Europe

As the pandemic continues to impact countries and cause untold suffering worldwide, our commitment has never been stronger to contribute to a global solution to this public health crisis.

Johnson & Johnson confirms that doses of its single-shot COVID-19 vaccine previously distributed to EU Member States, including Norway and Iceland, have met all product specifications and requirements for quality, safety and efficacy.

In alignment with the precautionary measures recommended by the European Medicines Agency (EMA), the Company will not release certain batches of its COVID-19 vaccines. We fully support the important quality and regulatory processes of health authorities across the world.

We will continue to work with health authorities on the approval of additional COVID-19 vaccine drug substance from our contract manufacturing partner, Emergent.

To meet our global commitments, the Company continues to scale its global manufacturing network, including substantially expanding our own manufacturing site in Leiden, the Netherlands, which is expected to come online in July, subject to regulatory approvals.

We believe that a single-shot, easy to distribute COVID-19 vaccine is an essential tool to combat the pandemic globally.

###

Cautions Concerning Forward-Looking Statements

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding development of a potential preventive vaccine for COVID-19. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Company, any of the other Janssen Pharmaceutical Companies, and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for

the fiscal year ended January 3, 2021, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in the company's most recently filed Quarterly Report on Form 10-Q, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.